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The Evolution of Molecular Genetic Pathology
Advancing 20th-Century Diagnostic Methods into Potent
Tools for the New Millennium
A fortuitous convergence of advancements in the past
decade has led to an explosion of new research in mo-
lecular pathology with consequent dramatic applications
to diagnosis, prognosis, and therapeutics, as well as a
clearer concept of the molecular pathogenesis of dis-
eases. The Human Genome Project not only provided the
impetus for advances in technology but also stimulated
the provision of funds for innovative research. Simulta-
neously, improvements in information technology have
led to a new paradigm, eloquently and succinctly ex-
pressed by award-winning columnist and author Thomas
Friedman in 2005 (http://www.thomaslfriedman.com) that
“The world is flat.” With the fruition of the Human Genome
Project, unexpected connections between diverse research
avenues have been made, and scientists studying as-
sumedly unrelated topics now discover on an almost daily
basis that they have been studying complementary parts of
the same conundrum.
The aforementioned events have been mirrored in the
content and growth of The Journal of Molecular Diagnostics
during its first 10 years. When the Journal was a mere
idea back in 1996, infectious diseases and hematological
disorders were the major areas of molecular diagnostic
application. Only the most prevalent inherited disorders
and a paucity of solid and soft tissue tumors were in the
realm of the molecular diagnostician. The first issue of the
JMD in November 1999 included a Special Report an-
nouncing molecular genetic pathology as a new joint
subspecialty of the American Board of Medical Genetics
and the American Board of Pathology. To date, more than
130 individuals are certified in this relatively new subspe-
cialty. In addition, the first issue of the JMD contained an
Editorial and a second Special Report by the Association
for Molecular Pathology (AMP) Training and Education
Committee on goals and objectives for molecular pathol-
ogy education in residency programs, as well as three
research articles related to embedding of fixed tissues for
DNA- and RNA-based genotyping, detection of minimal
residual disease in rhabdomyosarcomas, and fluores-
cence in situ hybridization (FISH) in lung cancer. Com-
pare those first 37 pages of journal content to the diver-
sity and sophistication of the 76 pages in the current
issue of JMD: a Review on parallel sequencing in clinical
diagnostics, two Consultations in Molecular Diagnostics
(cystic fibrosis and Gilbert’s syndrome), a Technical Ad-
vance (detection of FMR1), five research articles (pros-
thetic joint infection, detection of HER2 in breast cancer
by silver in situ hybridization (SISH), gene rearrange-
ments in lymphomas, array-based analysis of microRNA
in formalin-fixed, paraffin-embedded human tissue sam-
ples, and a rapid screening assay for KRAS mutations),
and a related Commentary on KRAS. Surely it can be
agreed that during the past decade, advances in molec-
ular pathology have morphed our parents’ and mentors’
diagnostic capability into a potent and powerful resource
for the betterment of mankind.
While such retrospection and comparative examina-
tion provide a historical perspective to where molecular
diagnostics exists today, it is the future of the field that
holds significant promise for even greater improvements
in health and the continued evolution of the JMD. In-
cluded below are forward outlooks and insights provided
by the Associate Editors of the JMD in their respective
areas of specialization.
Molecular Hematopathology: Excitement,
Bewilderment, and Future Promise
Hematopathology has a proud history of being at the
vanguard of the application of molecular technologies to
clinical laboratory diagnostics, with such pioneering con-
tributions as the application of antigen receptor (immu-
noglobulin and T-cell receptor) gene rearrangements to
the characterization of lymphoid malignancies. Cumber-
some and limited Southern blot approaches have been
succeeded by polymerase chain reaction (PCR)-based
approaches. However, the developmental flurry of nas-
cent amplification-dependent diagnostic assays came at
a price, particularly the lack of standardization and inabil-
Supplemental material for this article can be found on http://jmd.
amjpathol.org.
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ity to meaningfully compare data between laboratories.
The rigorous generation of standardized protocols for
these assays has been most welcome, and we look for-
ward to the development and adoption of standardized
diagnostic, prognostic, and monitoring assays.
The application of microarrays in the past decade to
hematological malignancies has been accompanied by
excitement, bewilderment, and confusion. It has been
exciting to witness the discovery of new genetic path-
ways in cancer biology, which has fostered tremendous
insights in our understanding of the genomic and cellular
biology of leukemias and lymphomas, allowing for more
robust classification, prognostication, and therapy. How-
ever, this has been accompanied by concern that such
approaches might supplant conventional (morphological
and immunophenotypic) tools, and even hematopatholo-
gists themselves. This is unlikely to occur, since these
technologies are best viewed as discovery tools, with the
new insights we uncover used by “traditional” hemato-
pathologists, who are most adeptly positioned to harness
their power. Another concern pertains to issues of lack of
validation and reproducibility of some microarray studies;
molecular hematopathologists will play an integral role in
resolving these issues, ensuring their judicious applica-
tion to diagnostics.
An additional area of new knowledge has been in the
discovery of the molecular underpinnings of neoplasms
that lack recurrent (or any) conventional cytogenetic ab-
normalities; thus, the area of molecular characterization
of, for example, karyotypically normal acute myeloid leu-
kemia has been and should continue to be an area of
growth in the meaningful classification of these neo-
plasms. The increasingly important arena of monitoring
patients with leukemia and lymphoma by quantitative
approaches has dramatically reshaped concepts of
remission and led to superior milestones to gauge re-
sponses, and indeed adjustments, to therapy, with the
therapy sometimes targeting a specific, and often dis-
ease-defining, molecular abnormality.
The application of functional genomics, such as by
using RNAi screens, will lead to the identification of novel
genetic defects. Similarly, the adoption of array compar-
ative genomic hybridization and single nucleotide poly-
morphism arrays will continue to refine our abilities to
characterize complex neoplasms in a more sophisticated
matter. The field of epigenomics is also poised to grow,
as we unravel transcriptional control defects in leukemia
and lymphoma, allowing for the development of novel
approaches to molecular diagnostics and therapeutics.
Molecular Testing for Microbiology
Molecular testing is now well integrated in the clinical
microbiology laboratory and for some pathogens has
revolutionized the diagnosis and management of infec-
tious diseases. Molecular methods were initially adapted
for slow-growing pathogens, such as viruses, and those
that required specialized methods or media. One of the
early success stories for the power of molecular detection
was in the diagnosis of herpes simplex virus (HSV)-asso-
ciated encephalitis. In the mid-1990’s testing for HSV
DNA in cerebral spinal fluid proved to be a sensitive and
specific alternative to brain biopsy, the previous gold
standard for establishing this diagnosis. This was shortly
followed by US Food and Drug Administration approval of
the first molecular microbiology test, which was used for
the detection of Chlamydia trachomatis from genital spec-
imens. With these events laboratorians and clinicians
developed an appreciation that this new technology was
a sensitive, rapid, and technically easy alternative to
conventional culture methods.
These early tests relied on PCR, but other amplification
methods, such as branched DNA and transcription-me-
diated amplification, also came into widespread use. As
technology evolved it became possible to quantify the
amount of virus directly from clinical specimens. Measur-
ing HIV-1 RNA in plasma became the first quantitative
test that was widely used clinically, allowing the individual
management of patients in a manner that was previously
not possible. The use of viral load testing progressed and
has been applied to the management of hepatitis C virus
(HCV) infections, as well as cytomegalovirus, Epstein-
Barr virus, and BK virus infections in bone marrow and
solid organ transplant recipients. As the clinical applica-
tions of molecular testing expanded, there were also
major advances in technologies, most notably the devel-
opment of real-time methods that enabled the simulta-
neous amplification and detection of target nucleic acid.
These methods reduced the turnaround time for testing to
a few hours and essentially eliminated the risk of car-
ryover contamination. Another important advantage for
viral load testing was the 6 to 7 log10 linear range of
real-time assays. All of these factors have contributed to
the rapid adaptation of real-time methods for routine use
in the clinical laboratory.
Advances in technology continue, and there are now
systems available, and others under development, that
fully automate all steps of testing including nucleic acid
extraction, amplification, and detection. The development
of these systems has progressed along two paths. There
are large, high-throughput automated systems that are
designed to increase efficiency for laboratories that per-
form high-volume testing for HIV-1 and HCV viral load as
well as the detection of C. trachomatis and Neisseria gon-
orrhoeae. There are also small, simple instruments that
allow addition of the primary specimen directly into a
cartridge or device with reporting of results within a few
hours. These random access instruments have on-board
controls and do not require highly trained technologists.
The availability of these types of testing systems will
undoubtedly bring molecular testing into more laborato-
ries and launch the possibility of near patient testing or
point-of-care testing for the diagnosis and management
of infectious diseases.
Although there has been tremendous progress in
molecular microbiology testing, challenges remain. Cur-
rently the majority of clinical laboratories do not perform
molecular microbiology testing. To increase access to
these important tests, simple platforms with a broad test
menu are needed. There are molecular tests for the identi-
fication of some bacterial pathogens directly from a clinical
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specimen, most notablymethicillin-resistant Staphylococcus
aureus. Moreover, simple sequencing methods and com-
prehensive databases are now available and are routinely
used in some referral and large clinical laboratories for the
identification of bacteria, mycobacteria, fungi, and parasites
that are not easily identified using conventional methods.
Currently, molecular methods have not replaced standard
culture methods for routine bacterial identification and sus-
ceptibility testing, and this is viewed by some as the next big
challenge. For molecular testing to replace the currently
used culture-based methods, advances in both technology
and our understanding of the genetics of pathogen resis-
tance are needed, if we are to move from phenotypic to
genotypic methods for susceptibility testing. Although there
are skeptics who feel this is not possible, with the advances
in molecular microbiology that have occurred in the past
decade, the potential for the next decade appears limitless.
Solid Tumor Molecular Diagnostics
Ten years ago, solid tumor molecular diagnostics was
a relatively limited area with few established assays,
notably HER2 FISH in breast cancer, translocation test-
ing in sarcomas, and perhaps microsatellite instability
testing in colorectal cancer. By the midpoint of the past
decade, a massive expansion of solid tumor molecular
diagnostics was already on the horizon, with the 2002
discovery of activating BRAF mutations in several cancer
types and of activating EGFR mutations in lung adenocar-
cinomas in 2004 (for further reading, see Supplemental
Material at http://jmd.amjpathol.org). As these mutations, es-
pecially the latter, are linked to sensitivity to specific new
targeted agents, and given the recent observation of the
value of KRAS mutations as predictors of resistance to
EGFR-targeted therapies in lung and colon cancers, the
volume of clinical testing in this area has grown rapidly, and
this growth is set to continue on a near-exponential trajec-
tory. (See Commentary by Associate Editor Marc Ladanyi in
this issue for more perspective on the predictive potential of
monitoring KRAS mutations.) The relatively genteel time
course of the development of HER2 FISH as a marker for
treatment selection in breast cancer is being tremendously
compressed in the case of these new discoveries. This
places new stresses on molecular diagnostic laboratories
as they are asked to develop and validate the correspond-
ing molecular predictive assays quickly and for an ever
widening range of mutations. Given the size of the solid
tumor oncology market, this testing area is also at risk for
novel types of pressure frompharmaceutical companies, as
the choice of predictive assay can in some cases change
the potential market for a given targeted agent by a factor of
2 or 3 or more.
Inherited Diseases: Genetic Testing—It’s Not
Just about Diagnosis
Ten years ago, the Secretary’s Advisory Committee on
Genetic Testing was formed, CNN announced that the
future of genetic testing had arrived, the US Federal
government passed laws barring large health insurers or
employers from using genetic testing to discriminate
against individuals, and the Human Genome Project re-
leased a map of the human genome. That map included
30,000 genes, which were estimated at the time to rep-
resent one-third of the total human genes. Full-scale hu-
man genome sequencing quickly ensued. In 2001, the
first draft sequence of the human genome was an-
nounced by both the National Institutes of Health (NIH)
Human Genome Project and the Celera Genomics
groups. The total number of human genes was revised as
30,000 to 35,000, with a subsequent revision of 20,000 to
25,000 when the Human Genome Project was completed
in 2003, a year that also marked the 50th anniversary of
Watson and Crick’s description of the double helix struc-
ture of DNA. The first part of this century saw an explosion
of completed genome sequences of both simple and
complex organisms including yeast, Archaea, Escherichia
coli, Mycobacterium tuberculosis, Caenorhabditis elegans,
Drosophila, Arabidopsis, rat, chicken, chimpanzee, trypano-
somatid, dog, rhesus macaque, and platypus.
Ten years ago the only private company talking about
DNA sequencing was Celera, using a shotgun sequenc-
ing strategy that complemented the mapping approach
of the NIH Human Genome Project. Now in 2008, we have
19 genome projects including the cancer genome and
microbiome. We strive to take the foundation that has
been laid in DNA sequence and understand the func-
tional organization and regulation of our genome se-
quence. We now know that the human genome consists
of probably only 20,000 genes, but there is extensive
“multitasking” (to coin the term used by Dr. Francis Col-
lins, former director of the National Human Genome Re-
search Institute) of expression in our genome with alter-
nate transcripts and processing contributing to genetic
diversity. Identifying the switches, triggers, exposures,
and interactions that control these proteins are the next
challenges for geneticists.
What will we do with our new genetic information and
disease risk factors? We are at the beginning of person-
alized medicine with gene-targeted therapies but not yet
realizing effective gene therapy. Expanded newborn
screening, pharmacogenomics, and nutrigenomics hold
promise to help us identify and perhaps attenuate our
individual genetic risks for disease susceptibility. “The
right drug at the right dose and the right time” is the aim
and perhaps the modern restatement of primum non no-
cere (first, do no harm). In the US we have recently
passed the Genetic Information Nondiscrimination Act
but also have personal genome companies marketing
directly to the public with vague promises of increased
understanding of genetics. The implications of our newly
found genetic knowledge continue to ripple through all
aspects of our society.
Ten to 15 years from now medicine will be quite differ-
ent as personalized medicine develops both diagnostics
and targeted treatments. With application of more em-
phasis on disease prevention and managing exposures
from our environment, diet, or lifestyle, we may signifi-
cantly influence the clinical outcome of our genetic risk.
As laboratory professionals we must engage in active
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education with our physician and health care colleagues
to aid the integration of these advances into routine pa-
tient care decisions. We are not limited by lack of good
ideas or methods or dedicated individuals but by decreas-
ing financial resources just at the time knowledge is boom-
ing.With the recent passing of Victor McKusick, the father of
human genetics, let us renew our efforts to strive for respon-
sible application of our understanding of our genomes to
improve the diagnosis and treatment of genetic disorders
including equal access to medical care for all of our citizens
as well as to all global populations in need.
Closing Remarks
As we move further into the new millennium, the use-
fulness and ease of implementation of molecular test-
ing will no doubt continue expanding. The evolution of
molecular diagnostics (as well as molecular prognos-
tics and therapeutics) will continue to improve health
care and quality of life into the future, and The Journal
of Molecular Diagnostics will continue to lead the way in
molecular medicine and analysis of new assay devel-
opments.
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